Understand the source comparison
Adamax vs Other Growth Hormone Secretagogues: Research Comparison
The growth hormone secretagogue landscape includes ghrelin mimetics (GHRP-2, GHRP-6, Hexarelin, Ipamorelin), GHRH analogs (Sermorelin, CJC-1295, Tesamorelin), and synthetic secretagogues (MK-677). Each category activates growth hormone release through distinct
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The growth hormone secretagogue landscape includes ghrelin mimetics (GHRP-2, GHRP-6, Hexarelin, Ipamorelin), GHRH analogs (Sermorelin, CJC-1295, Tesamorelin), and synthetic secretagogues (MK-677). Each category activates growth hormone release through distinct mechanisms, and understanding these differences determines which compound fits specific research objectives.
- Adamax (GHRP-2 + GHRH)
- Dual GHS-R1a and GHRH receptor agonism
- 4.5–6×
- 2–3 hours
- High. Minimal cortisol/prolactin elevation
- Best choice for studying physiological GH pulsatility; synergistic effect allows lower individual peptide doses; requires precise timing relative to circadian rhythm
- GHRP-2 (monotherapy)
- GHS-R1a agonist; somatostatin inhibition
- 2–3×
- Moderate. Transient cortisol elevation at high doses
- Effective as single agent but produces shorter-duration pulses; useful for appetite regulation studies due to ghrelin pathway activation
- Ipamorelin
- Selective GHS-R1a agonist
- 2–2.5×
- 2 hours
- Very high. No cortisol/prolactin effect
- Most selective ghrelin mimetic; ideal when isolating GH effects from ACTH/prolactin pathways; lower peak amplitude limits use in maximal-stimulation protocols
- MK-677 (Ibutamoren)
- Oral GHS-R1a agonist
- 1.8–2.5× (sustained)
- 24 hours
- Moderate. Dose-dependent cortisol elevation
- Only oral-active secretagogue; produces sustained elevation rather than pulses; useful for chronic administration studies but doesn't replicate physiological secretion patterns
- Sermorelin (monotherapy)
- GHRH receptor agonist
- 1.5–2×
- 10–20 minutes (very short)
- High. Pure GHRH pathway
- Rapid onset but brief duration; requires continuous infusion for sustained effect; primarily used as diagnostic agent in GH deficiency testing rather than research tool
- CJC-1295 No DAC
- 30 minutes
- Longer-acting than Sermorelin; still requires combination with GHRP for synergy; DAC version (CJC-1295 with DAC) has 6–8 day half-life but produces non-pulsatile elevation
- The critical insight most comparison guides miss: peak GH amplitude matters less than pulse frequency and duration for most metabolic endpoints. A 6× GH pulse lasting 90 minutes produces different downstream effects than sustained 2× elevation over 12 hours, even when total AUC is equivalent. IGF-1 upregulation in liver and skeletal muscle responds to pulse amplitude, while lipolysis in adipose tissue responds to cumulative GH exposure duration. Adamax's pulsatile profile makes it suited for studies examining IGF-1-mediated anabolic effects, whereas MK-677's sustained elevation is better for fat oxidation and glucose metabolism studies.
- The synergy between GHRP-2 and GHRH components isn't unique to Adamax. Any GHRP/GHRH combination produces similar amplification. What distinguishes Adamax as a formulated blend is consistent molar ratio and pre-verified compatibility. When researchers mix peptides in-house from separate vials, concentration calculation errors and pH incompatibility between storage solutions can cause immediate precipitation or gradual aggregation that invalidates dose assumptions. Pre-formulated blends eliminate that variable, though they sacrifice dosing flexibility for researchers who need to titrate individual components independently.